The latest installment in BioPharma Dive’s data visualization series features a look at the emerging popularity of RNAi ...

Following exits for its subsidiaries Electra Therapeutics and Vega Therapeutics, Star is now mining for a new drug prospect.

Funds from the upsized offering will support a trio of protein-degrading medicines in development for allergic conditions as well as the autoimmune disorder Graves’ disease.

A combination of the shot and the immunotherapy Keytruda cut the risk of relapse or death by 42% in a landmark melanoma study that met Wall Street expectations but triggered a “sell-the-news reaction, ...

U.S. regulators have accepted a new submission for Vyglxia, offering the chance at a turnaround for another rare disease ...

Lower-than-expected sales of Xolair stood out as the Swiss drugmaker readies for an onslaught of generic competition for top products.

Hibsago is viewed as a potential “functional cure” for chronic infections and an important part of the British drugmaker’s ...

Shortly after winning a clearance in the skin disease dermatomyositis, brepocitinib posted results suggesting it might also ...

Today, a brief rundown of news involving Arcus Biosciences and Eli Lilly, as well as updates from TriGemX Bio and AstraZeneca that you may have missed. Eli Lilly is teaming up with Hong Kong-based ...